Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | BCL3 | P20749 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311145 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2ARXFP1KDM4EMAPT | |
| SCHEMBL21311447 | 0.85 | TSHR (0.64) | SMN1; SMN2KMT2ARXFP1KDM4EMAPT | |
| SCHEMBL21311153 | 0.79 | LPAR1 (0.54) | SMN1; SMN2KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL10330502 | 0.78 | KCNA3 (0.70) | LMNAALDH1A1HPGDNPC1POLB | |
| SCHEMBL24801414 | 0.76 | TAAR1 (0.57) | SMN1; SMN2KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL24598461 | 0.76 | POLB (0.50) | SMN1; SMN2KMT2ALMNAHPGDNPC1 | |
| SCHEMBL10330509 | 0.75 | LMNA (0.58) | SMN1; SMN2KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL1918788 | 0.74 | KDM4E (0.64) | SMN1; SMN2KMT2ALMNAKDM4EMAPT | |
| SCHEMBL8671118 | 0.73 | KMT2A (0.68) | KMT2ARXFP1LMNAMAPTALDH1A1 | |
| SCHEMBL24571699 | 0.72 | KMT2A (0.60) | SMN1; SMN2KMT2ALMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | SMN1; SMN2 959/4885KMT2A 2961/4885RXFP1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.